ARMO BioSciences’s Phase 1b Trials Demonstrate Continued Promising Response Rates and Survival in Patients with Advanced Pancreatic Cancer, NSCLC, and RCC

posted in: ARMO, News | 0

ARMO BioSciences’s Phase 1b Trials Demonstrate Continued Promising Response Rates and Survival in Patients with Advanced Pancreatic Cancer, NSCLC, and RCC   ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced that clinical trial results on its lead investigational immuno-oncology … Continued

Selecta Biosciences Announces $50 Million Private Placement

posted in: News | 0

Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced that it has entered into definitive agreements to sell securities in a private placement that is expected … Continued